Literature DB >> 19953309

Mucosal vaccines: recent progress in understanding the natural barriers.

Olga Borges1, Filipa Lebre, Dulce Bento, Gerrit Borchard, Hans E Junginger.   

Abstract

It has long been known that protection against pathogens invading the organism via mucosal surfaces correlates better with the presence of specific antibodies in local secretions than with serum antibodies. The most effective way to induce mucosal immunity is to administer antigens directly to the mucosal surface. The development of vaccines for mucosal application requires antigen delivery systems and immunopotentiators that efficiently facilitate the presentation of the antigen to the mucosal immune system. This review provides an overview of the events within mucosal tissues that lead to protective mucosal immune responses. The understanding of those biological mechanisms, together with knowledge of the technology of vaccines and adjuvants, provides guidance on important technical aspects of mucosal vaccine design. Not being exhaustive, this review also provides information related to modern adjuvants, including polymeric delivery systems and immunopotentiators.

Mesh:

Substances:

Year:  2009        PMID: 19953309     DOI: 10.1007/s11095-009-0011-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  121 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Man the barrier! Strategic defences in the intestinal mucosa.

Authors:  C Nagler-Anderson
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

Review 3.  Exploiting M cells for drug and vaccine delivery.

Authors:  M A Clark; M A Jepson; B H Hirst
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

4.  Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-07-06       Impact factor: 15.470

Review 5.  Microparticles as vaccine adjuvants and delivery systems.

Authors:  Derek T O'Hagan; Manmohan Singh
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

6.  IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut.

Authors:  Takashi Shikina; Takachika Hiroi; Kohichi Iwatani; Myoung Ho Jang; Satoshi Fukuyama; Manabu Tamura; Takeshi Kubo; Hiromichi Ishikawa; Hiroshi Kiyono
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

7.  Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

Authors:  Hans-Joachim Mollenkopf; Guido Dietrich; Joachim Fensterle; Leander Grode; Klaus-Dieter Diehl; Bernhard Knapp; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Stefan H E Kaufmann
Journal:  Vaccine       Date:  2004-07-29       Impact factor: 3.641

8.  Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.

Authors:  Monika Manocha; Pramod Chandra Pal; K T Chitralekha; Beena Elizabeth Thomas; Vinita Tripathi; Siddhartha Dutta Gupta; Ramesh Paranjape; Smita Kulkarni; D Nageswara Rao
Journal:  Vaccine       Date:  2005-07-27       Impact factor: 3.641

9.  Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.

Authors:  Bethany Hansen; Anna Sokolovska; Harm HogenEsch; Stanley L Hem
Journal:  Vaccine       Date:  2007-07-16       Impact factor: 3.641

Review 10.  Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.

Authors:  Stanley L Hem; Harm Hogenesch
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

View more
  20 in total

1.  Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization.

Authors:  Catherine A Fromen; Gregory R Robbins; Tammy W Shen; Marc P Kai; Jenny P Y Ting; Joseph M DeSimone
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

2.  Novel antigen delivery technologies: a review.

Authors:  Deepika Jain; Vikas Jain; Ranjit Singh
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

Review 3.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 4.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

Review 5.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

6.  Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Authors:  Bala Vamsi K Karuturi; Shailendra B Tallapaka; Joy A Phillips; Sam D Sanderson; Joseph A Vetro
Journal:  Clin Immunol       Date:  2015-06-23       Impact factor: 3.969

7.  Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking.

Authors:  Paul E Makidon; Igor M Belyakov; Luz P Blanco; Katarzyna W Janczak; Jeffrey Landers; Anna U Bielinska; Jeffrey V Groom; James R Baker
Journal:  Eur J Immunol       Date:  2012-07-04       Impact factor: 5.532

8.  Mucosal adjuvanticity of fibronectin-binding peptide (FBP) fused with Echinococcus multilocularis tetraspanin 3: systemic and local antibody responses.

Authors:  Zhisheng Dang; Jinchao Feng; Kinpei Yagi; Chihiro Sugimoto; Wei Li; Yuzaburo Oku
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

9.  Cochleates derived from Vibrio cholerae O1 proteoliposomes: the impact of structure transformation on mucosal immunisation.

Authors:  Reinaldo Acevedo; Oliver Pérez; Caridad Zayas; José L Pérez; Adriana Callicó; Bárbara Cedré; Luis García; David Mckee; Alexander B Mullen; Valerie A Ferro
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

10.  Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination.

Authors:  Sae-Hae Kim; Kyung-Yeol Lee; Yong-Suk Jang
Journal:  Immune Netw       Date:  2012-10-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.